Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at William Blair lifted their Q2 2025 earnings estimates for Larimar Therapeutics in a report released on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.50) for the quarter, up from their previous forecast of ($0.51). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and FY2026 earnings at ($2.05) EPS.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).
LRMR has been the topic of several other research reports. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Truist Financial initiated coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price target for the company. Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Finally, HC Wainwright lifted their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $19.63.
View Our Latest Stock Analysis on Larimar Therapeutics
Larimar Therapeutics Stock Performance
Shares of LRMR stock remained flat at $2.24 during trading hours on Monday. The stock had a trading volume of 168,842 shares, compared to its average volume of 751,119. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $11.20. The stock has a market cap of $143.42 million, a PE ratio of -1.95 and a beta of 0.93. The firm has a 50-day moving average price of $2.31 and a two-hundred day moving average price of $4.10.
Institutional Investors Weigh In On Larimar Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in Larimar Therapeutics during the fourth quarter valued at $25,000. Virtu Financial LLC acquired a new stake in shares of Larimar Therapeutics during the 3rd quarter valued at about $71,000. Algert Global LLC purchased a new position in shares of Larimar Therapeutics in the 4th quarter valued at about $47,000. China Universal Asset Management Co. Ltd. acquired a new position in Larimar Therapeutics in the 4th quarter worth about $52,000. Finally, Graham Capital Management L.P. purchased a new position in Larimar Therapeutics during the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 91.92% of the company's stock.
About Larimar Therapeutics
(
Get Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Recommended Stories

Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.